Related references
Note: Only part of the references are listed.Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study
Piero Barbanti et al.
HEADACHE (2021)
Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study
Maria Michela Cainazzo et al.
NEUROLOGICAL SCIENCES (2021)
Efficacy of erenumab in chronic migraine patients with and without ictal allodynia
Richard B. Lipton et al.
CEPHALALGIA (2021)
Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
Lanfranco Pellesi et al.
HEADACHE (2020)
Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
Raffaele Ornello et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
Bianca Raffaelli et al.
FRONTIERS IN NEUROLOGY (2020)
European headache federation consensus on the definition of resistant and refractory migraine Developed with the endorsement of the European Migraine & Headache Alliance (EMHA)
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
Antonio Russo et al.
JOURNAL OF HEADACHE AND PAIN (2020)
A prospective real-world analysis of erenumab in refractory chronic migraine
Giorgio Lambru et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
Armin Scheffler et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Effectiveness of erenumab in chronic migraine patients with associated medication overuse headache: a prospective observational study
Marcella Curone et al.
NEUROLOGICAL SCIENCES (2020)
Erenumab efficacy in highly resistant chronic migraine: a real-life study
Umberto Pensato et al.
NEUROLOGICAL SCIENCES (2020)
Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center
Eleonora Matteo et al.
NEUROLOGICAL SCIENCES (2020)
CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review
Ivan Urits et al.
CURRENT PAIN AND HEADACHE REPORTS (2019)
Erenumab: from scientific evidence to clinical practicethe first Italian real-life data
Piero Barbanti et al.
NEUROLOGICAL SCIENCES (2019)
CGRP and headache: a brief review
Stewart J. Tepper
NEUROLOGICAL SCIENCES (2019)
Erenumab in chronic migraine with medication overuse Subgroup analysis of a randomized trial
Stewart J. Tepper et al.
NEUROLOGY (2019)
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
Messoud Ashina et al.
CEPHALALGIA (2019)
The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
Raffaele Ornello et al.
JOURNAL OF HEADACHE AND PAIN (2019)
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Clinical significance of sensory hypersensitivities in migraine patients: does allodynia have a priority on it?
Jong-Geun Seo et al.
NEUROLOGICAL SCIENCES (2019)
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
David W. Dodick et al.
CEPHALALGIA (2018)
Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
Lars Bendtsen et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Uwe Reuter et al.
LANCET (2018)
Blocking CGRP in migraine patients - a review of pros and cons
Marie Deen et al.
JOURNAL OF HEADACHE AND PAIN (2017)
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart Tepper et al.
LANCET NEUROLOGY (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Brain plasticity and migraine transformation: fMRI evidences
Carlo Lovati et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Brain plasticity and migraine transformation: fMRI evidences
Carlo Lovati et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review
Michel Lanteri-Minet et al.
CEPHALALGIA (2011)
Global prevalence of chronic migraine: A systematic review
J. L. Natoli et al.
CEPHALALGIA (2010)
Refractory headache: Historical perspective, need, and purposes for an operational definition
Elliott A. Schulman et al.
HEADACHE (2008)
Defining refractory migraine and refractory chronic migraine: Proposed criteria from the refractory headache special interest section of the American Headache Society
Elliott A. Schulman et al.
HEADACHE (2008)
Headache Impact Test-6 (HIT-6) Scores for Migraine Patients: Their Relation to Disability as Measured from a Headache Diary
Hae Eun Shin et al.
JOURNAL OF CLINICAL NEUROLOGY (2008)
When should chronic migraine patients be considered refractory to pharmacological prophylaxis
Domenico D'Amico et al.
NEUROLOGICAL SCIENCES (2008)
Identifying cutaneous allodynia in chronic migraine using a practical clinical method
A. Ashkenazi et al.
CEPHALALGIA (2007)
Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders
P Sarchielli et al.
CEPHALALGIA (2006)